These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 37977064)
21. Immunotherapeutic applications of IL-15. Croce M; Orengo AM; Azzarone B; Ferrini S Immunotherapy; 2012 Sep; 4(9):957-69. PubMed ID: 23046239 [TBL] [Abstract][Full Text] [Related]
22. Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. Gao X; Wang X; Yang Q; Zhao X; Wen W; Li G; Lu J; Qin W; Qi Y; Xie F; Jiang J; Wu C; Zhang X; Chen X; Turnquist H; Zhu Y; Lu B J Immunol; 2015 Jan; 194(1):438-45. PubMed ID: 25429071 [TBL] [Abstract][Full Text] [Related]
23. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic gene modified cell based cancer vaccines. Kozłowska A; Mackiewicz J; Mackiewicz A Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846 [TBL] [Abstract][Full Text] [Related]
25. Interleukin-21: basic biology and implications for cancer and autoimmunity. Spolski R; Leonard WJ Annu Rev Immunol; 2008; 26():57-79. PubMed ID: 17953510 [TBL] [Abstract][Full Text] [Related]
31. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy. Dhupkar P; Gordon N Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. Carnevalli LS; Ghadially H; Barry ST Front Immunol; 2021; 12():633685. PubMed ID: 33953710 [TBL] [Abstract][Full Text] [Related]
33. The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy. Li MS; Liu Z; Liu JQ; Zhu X; Liu Z; Bai XF Immunotherapy; 2015; 7(2):191-200. PubMed ID: 25713993 [TBL] [Abstract][Full Text] [Related]
34. Interleukin 21 - its potential role in the therapy of B-cell lymphomas. Bhatt S; Sarosiek KA; Lossos IS Leuk Lymphoma; 2017 Jan; 58(1):17-29. PubMed ID: 27405876 [TBL] [Abstract][Full Text] [Related]
36. IL-33/ST2 as a potential target for tumor immunotherapy. Jiang W; Lian J; Yue Y; Zhang Y Eur J Immunol; 2021 Aug; 51(8):1943-1955. PubMed ID: 34131922 [TBL] [Abstract][Full Text] [Related]
37. [Interleukin-34: a key molecule in the tumor microenvironment]. Kajihara N; Seino KI Rinsho Ketsueki; 2021; 62(8):1302-1307. PubMed ID: 34497220 [TBL] [Abstract][Full Text] [Related]
38. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Zhang W; Zhao Z; Li F Mol Immunol; 2022 Apr; 144():58-70. PubMed ID: 35203022 [TBL] [Abstract][Full Text] [Related]
39. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. Soler MF; Abaurrea A; Azcoaga P; Araujo AM; Caffarel MM J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37945321 [TBL] [Abstract][Full Text] [Related]
40. IL-32 and its paradoxical role in neoplasia. Hough JT; Zhao L; Lequio M; Heslin AJ; Xiao H; Lewis CC; Zhang J; Bai Q; Wakefield MR; Fang Y Crit Rev Oncol Hematol; 2023 Jun; 186():104011. PubMed ID: 37105370 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]